- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Patent holdings for IPC class C07D 403/04
Total number of patents in this class: 7446
10-year publication summary
|
490
|
475
|
497
|
523
|
468
|
426
|
493
|
389
|
366
|
29
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Patent GmbH | 5727 |
150 |
| Bristol-myers Squibb Company | 4795 |
119 |
| Novartis AG | 10494 |
107 |
| Boehringer Ingelheim International GmbH | 4595 |
91 |
| Janssen Pharmaceutica N.V. | 3340 |
85 |
| Bayer AG | 3409 |
77 |
| F. Hoffmann-La Roche AG | 7893 |
75 |
| Syngenta Crop Protection AG | 6335 |
75 |
| AstraZeneca AB | 2833 |
73 |
| Merck Sharp & Dohme LLC | 3751 |
68 |
| Takeda Pharmaceutical Company Limited | 2710 |
67 |
| LG Chem, Ltd. | 17741 |
66 |
| Dana-Farber Cancer Institute, Inc. | 2640 |
62 |
| Hoffmann-La Roche Inc. | 3602 |
61 |
| Rohm and Haas Electronic Materials Korea Ltd. | 333 |
59 |
| Genentech, Inc. | 4040 |
55 |
| Vertex Pharmaceuticals Incorporated | 1624 |
52 |
| Araxes Pharma LLC | 92 |
50 |
| Abbvie Inc. | 1820 |
47 |
| Syngenta Participations AG | 1647 |
45 |
| Other owners | 5962 |